<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Diagnosis and treatment of Talaromyces (Penicillium) marneffei infection
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Diagnosis and treatment of Talaromyces (Penicillium) marneffei infection
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Diagnosis and treatment of Talaromyces (Penicillium) marneffei infection
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Khuanchai Supparatpinyo, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carol A Kauffman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 25, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Talaromyces
         </em>
         <em>
          marneffei
         </em>
         (formerly
         <em>
          Penicillium marneffei
         </em>
         ) is an important cause of morbidity and mortality in patients with AIDS, as well as other immunocompromised individuals who live in or are from Southeast Asia [
         <a href="#rid1">
          1
         </a>
         ]. On occasion, it can also cause disease in such patients who have had travel-related exposure to this organism.
         <em>
          Penicillium
         </em>
         <em>
          marneffei
         </em>
         was renamed
         <em>
          Talaromyces marneffei
         </em>
         in 2015, and the disease, which had been referred to as penicilliosis, is now called talaromycosis.
        </p>
        <p>
         For individuals with HIV, this systemic fungal infection was commonly diagnosed prior to the era of potent antiretroviral therapy (ART). The widespread use of ART has led to a significant decline of opportunistic infections, including
         <em>
          T. marneffei
         </em>
         infection, in highly endemic areas. However, despite the widespread availability of ART,
         <em>
          T. marneffei
         </em>
         infection continues to cause considerable morbidity and mortality in AIDS patients who are unaware of their HIV infection, who do not have access to ART, or who have a suboptimal response to HIV therapy.
        </p>
        <p>
         The diagnosis and treatment of
         <em>
          T. marneffei
         </em>
         will be reviewed here. The mycology, epidemiology, and clinical manifestations of
         <em>
          T. marneffei
         </em>
         are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3033.html" rel="external">
          "Epidemiology and clinical manifestations of Talaromyces (Penicillium) marneffei infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H2884129835">
         <span class="h2">
          Approach to diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of talaromycosis (formerly called penicilliosis) should be considered in patients who live in or are from Southeast Asia, northern Australia, South Asia (including India), and China who present with fever, weight loss, nonproductive cough, skin lesions, hepatosplenomegaly, and/or generalized lymphadenopathy. Talaromycosis typically occurs in patients who are severely immunocompromised (eg, those with AIDS); however, cases have also been reported in those with other underlying conditions (eg, autoimmune disorders, cancer, diabetes) [
         <a href="#rid2">
          2-4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3033.html" rel="external">
          "Epidemiology and clinical manifestations of Talaromyces (Penicillium) marneffei infection", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
         A definitive diagnosis is usually made by culture of the fungus from blood, skin biopsy, bone marrow, or lymph nodes. However, given the need for early treatment, a presumptive diagnosis can be made by demonstrating the characteristic morphologic findings of this fungus in biopsy material or in blood smears of patients with fungemia  (
         <a class="graphic graphic_picture graphicRef58588" href="/z/d/graphic/58588.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid1">
          1,5,6
         </a>
         ].
         <em>
          T. marneffei (
         </em>
         formerly
         <em>
          P. marneffei)
         </em>
         appear as oval or elongated yeast-like organisms with a clearly defined central septum. The presence of a centrally located transverse septum (eg, "cross wall") differentiates
         <em>
          T. marneffei
         </em>
         from
         <em>
          Histoplasma capsulatum
         </em>
         (
         <a class="graphic graphic_picture graphicRef71699" href="/z/d/graphic/71699.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1516959136">
         <span class="h2">
          Diagnostic tests
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h3">
          Culture
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          T. marneffei
         </em>
         can be readily isolated from various clinical specimens. Cultures of bone marrow and lymph node biopsies are the most sensitive, followed by cultures of skin lesions and blood (including conventional blood culture systems)  (
         <a class="graphic graphic_table graphicRef62907" href="/z/d/graphic/62907.html" rel="external">
          table 1
         </a>
         ).
         <em>
          T. marneffei
         </em>
         has also been isolated from cultures of stool, urine, cerebrospinal fluid (CSF), and joint fluid [
         <a href="#rid8">
          8-10
         </a>
         ].
        </p>
        <p>
         The organism typically takes about four to seven days to grow; however, on occasion, growth can take a few weeks to occur. Fungal cultures at 25°C on Sabouraud dextrose agar demonstrate characteristic features that include a flat green surface and underlying deep red coloring  (
         <a class="graphic graphic_picture graphicRef76600" href="/z/d/graphic/76600.html" rel="external">
          picture 3
         </a>
         ). Microscopically, the fungus has typical filamentous reproductive structures of the genus
         <em>
          Penicillium
         </em>
         (
         <a class="graphic graphic_picture graphicRef78922" href="/z/d/graphic/78922.html" rel="external">
          picture 4
         </a>
         ).
        </p>
        <p>
         Before confirming that an isolate is
         <em>
          T. marneffei
         </em>
         ,
         <em>
         </em>
         mold-to-yeast conversion must be demonstrated. This can be achieved by subculturing the fungus onto brain-heart-infusion agar and incubating it at 37°C. Alternative methods for confirming the diagnosis are through a polymerase chain reaction (PCR) hybridization assay, which can be used to rapidly identify the organism that has been grown in culture [
         <a href="#rid11">
          11
         </a>
         ], or an exoantigen test [
         <a href="#rid12">
          12
         </a>
         ]
         <em>
          .
         </em>
         (See
         <a class="medical medical_review" href="/z/d/html/3033.html" rel="external">
          "Epidemiology and clinical manifestations of Talaromyces (Penicillium) marneffei infection", section on 'Mycology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          Histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the proper epidemiologic setting, a presumptive diagnosis of
         <em>
          T. marneffei
         </em>
         infection can be made several days before the cultures are positive by visualizing the organism. The organism can be identified through microscopic examination of any of the following: Wright-stained samples of blood or bone marrow; touch smears of skin or lymph node biopsies; or Giemsa-stained bronchoalveolar lavage fluid [
         <a href="#rid1">
          1,9,13,14
         </a>
         ].
        </p>
        <p>
         Wright-stained samples show intracellular and extracellular basophilic, spherical, oval, and elliptical yeast-like organisms. Some of these cells have a clearly defined central septum, which is a characteristic feature of
         <em>
          T. marneffei
         </em>
         (
         <a class="graphic graphic_picture graphicRef58588" href="/z/d/graphic/58588.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef79630" href="/z/d/graphic/79630.html" rel="external">
          picture 5
         </a>
         ). The cell wall and the cytoplasm of
         <em>
          T. marneffei
         </em>
         cells cannot be seen well with hematoxylin-eosin staining of tissue sections. Thus, methenamine silver or periodic acid-Schiff (PAS) staining is preferred, and the organisms appear as unicellular round to oval cells within macrophages or histiocytes. Extracellular elongated or sausage-shaped cells with one or two septa may also be seen.
        </p>
        <p>
         Descriptions of the histologic appearance of
         <em>
          T. marneffei
         </em>
         include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study of liver biopsies from 30 patients with HIV and disseminated
         <em>
          T. marneffei
         </em>
         infection, histopathologic findings were classified into one of three patterns: diffuse, granulomatous, and mixed [
         <a href="#rid15">
          15
         </a>
         ]. The first pattern showed a diffuse infiltration of foamy macrophages that contained numerous
         <em>
          T. marneffei
         </em>
         organisms. The granulomatous pattern showed multiple granulomata with various degrees of inflammatory cell infiltration. The mixed pattern showed features intermediate between the first two categories.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intracellular and extracellular yeast forms with the characteristic cross-septation of
         <em>
          T. marneffei
         </em>
         have been visualized in specimens obtained by fine needle aspiration of lymph nodes in patients with HIV and lymphadenopathy [
         <a href="#rid16">
          16
         </a>
         ]. This technique is particularly helpful in cases in which there are no skin lesions and enlarged lymph nodes are confined to the deep intra-abdominal region.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Serology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serologic assays are not widely used because of limited data regarding diagnostic accuracy and restricted availability of the required commercial reagents [
         <a href="#rid17">
          17
         </a>
         ]. Research to assess various methods of serologic testing in both symptomatic and asymptomatic patients is ongoing. Tests that are being investigated include indirect fluorescent antibody tests, enzyme-linked immunosorbent assays (ELISAs), and Western immunoblot tests [
         <a href="#rid16">
          16,18,19
         </a>
         ]. Whether serologic testing could enable the identification of asymptomatic individuals who may benefit from pre-emptive treatment is unknown.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Molecular diagnostics
         </span>
         <span class="headingEndMark">
          —
         </span>
         PCR-based techniques using serum or urine are not currently used to diagnose
         <em>
          T. marneffei
         </em>
         in the clinical setting [
         <a href="#rid17">
          17,18,20-26
         </a>
         ]. However,
         <em>
          T. marneffei
         </em>
         has been identified using immunohistochemical techniques
         <em>
         </em>
         in tissues and through PCR testing of a skin biopsy specimen using a set of primers specific for the fungus [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H591357454">
         <span class="h3">
          Antigen detection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antigen testing (immunodiffusion, latex agglutination, or ELISA) is not routinely available for diagnosis. However, galactomannan testing, which is primarily used for detection of aspergillosis, can show cross-reactivity with
         <em>
          T. marneffei
         </em>
         [
         <a href="#rid28">
          28
         </a>
         ]. As an example, in one case series, positive serum galactomannan tests were reported in three patients who had pulmonary infiltrates secondary to culture-proven
         <em>
          T. marneffei
         </em>
         infection [
         <a href="#rid29">
          29
         </a>
         ]. However, the titers in patients with talaromycosis are lower than those noted in patients with aspergillosis, and this test cannot be relied upon for diagnosis [
         <a href="#rid30">
          30
         </a>
         ]. A more detailed discussion of galactomannan testing is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/15717.html" rel="external">
          "Diagnosis of invasive aspergillosis", section on 'Galactomannan antigen detection'
         </a>
         .)
        </p>
        <p>
         New antigen tests, such as the Mp1P ELISA, are in development. This test can detect antigen in plasma and urine, and in one report, the Mp1P ELISA had improved sensitivity and time to diagnosis compared with blood culture [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1381372939">
         <span class="h2">
          Evaluation for immunocompromising conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients diagnosed with talaromycosis and who are not known to be immunocompromised (eg, HIV), we evaluate for immunocompromise by performing a history and physical, age-appropriate cancer screening, and testing for HIV, diabetes, autoimmune diseases, and presence of anti-interferon gamma autoantibody [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis for an individual with AIDS who is from Southeast Asia, northern Australia, South Asia (including India), or China and presents with skin lesions, cough, and constitutional symptoms includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tuberculosis – Patients with
         <em>
          Mycobacterium tuberculosis
         </em>
         and
         <em>
          T. marneffei
         </em>
         can present with fever, weight loss, cough, and lymphadenopathy. However, skin lesions are uncommon in patients with tuberculosis, whereas they are commonly seen in patients with talaromycosis. These infections are best distinguished by special stains to identify the organism and/or by culture. (See
         <a class="medical medical_review" href="/z/d/html/7026.html" rel="external">
          "Pulmonary tuberculosis: Clinical manifestations and complications"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8024.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of miliary tuberculosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Melioidosis – Both melioidosis (caused by
         <em>
          Burkholderia pseudomallei
         </em>
         ) and talaromycosis can present with cough and a localized skin infection. Patients with melioidosis can also present with genitourinary symptoms (eg, suprapubic pain, dysuria, difficulty passing urine, or acute urinary retention requiring catheterization), septic arthritis, and/or encephalomyelitis. For both infections, the diagnosis is typically made through microscopy and/or culture. (See
         <a class="medical medical_review" href="/z/d/html/3146.html" rel="external">
          "Melioidosis: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Histoplasmosis – Patients with talaromycosis and histoplasmosis often present with fever, night sweats, fatigue, weight loss, and cough [
         <a href="#rid32">
          32
         </a>
         ]. In addition, physical examination may demonstrate hepatosplenomegaly, lymphadenopathy, and skin lesions. Bedside microscopic examination of scrapings from these skin lesions can lead to the correct diagnosis of
         <em>
          T. marneffei
         </em>
         due to its unique morphology. By contrast,
         <em>
          H. capsulatum
         </em>
         is often diagnosed through the use of urinary antigen testing. However, the urine antigen test used to diagnose histoplasmosis is often positive in patients with
         <em>
          T. marneffei
         </em>
         infection because these organisms share similar galactomannan cell wall constituents [
         <a href="#rid33">
          33,34
         </a>
         ]. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2455.html" rel="external">
          "Pathogenesis and clinical manifestations of disseminated histoplasmosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6991.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of histoplasmosis in patients with HIV"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H4759011">
         <span class="h2">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antifungal treatment should be initiated as soon as possible in all patients with talaromycosis. The mortality rate has been reported to be as high as 97 percent if the infection goes untreated or if there is a delay in diagnosis [
         <a href="#rid1">
          1,35,36
         </a>
         ]. This is particularly true for patients with moderate or severe disease [
         <a href="#rid36">
          36
         </a>
         ]. The use of antifungal therapy has resulted in clinical and microbiologic resolution of infection in up to 95 percent of patients [
         <a href="#rid1">
          1,37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H277068659">
         <span class="h2">
          Antifungal therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Amphotericin B and
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         are the agents typically used to treat
         <em>
          T. marneffei
         </em>
         infection. For those who cannot take amphotericin B or itraconazole,
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         can be used.
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          Fluconazole
         </a>
         has poor activity [
         <a href="#rid35">
          35
         </a>
         ], and there are insufficient clinical data to recommend treatment with an echinocandin.
        </p>
        <p class="headingAnchor" id="H2817048920">
         <span class="h3">
          Treatment approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to treatment of talaromycosis is the same for individuals with and without HIV and depends upon the severity of disease (see
         <a class="medical medical_review" href="/z/d/html/3033.html" rel="external">
          "Epidemiology and clinical manifestations of Talaromyces (Penicillium) marneffei infection", section on 'Clinical manifestations'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe disease is characterized by multiple organ involvement with respiratory failure or circulatory collapse.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate disease is characterized by multiple organ involvement without respiratory failure or cardiovascular collapse.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mild disease refers to patients who only have skin lesions and no fungemia.
        </p>
        <p>
        </p>
        <p>
         Patients with talaromycosis should receive induction and consolidation therapy followed by long-term maintenance therapy until restoration of cellular immunity. Nonpregnant patients with moderate to severe disease should be treated initially with amphotericin B and then transitioned to
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         . Those with mild disease can receive itraconazole for the entire treatment duration.
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          Voriconazole
         </a>
         is an alternative agent for those who cannot take amphotericin or itraconazole. In pregnant patients, the approach must be individualized given the risk of teratogenicity with azole agents. (See
         <a class="local">
          'Induction and consolidation therapy'
         </a>
         below and
         <a class="local">
          'Maintenance therapy (secondary prophylaxis)'
         </a>
         below and
         <a class="local">
          'Considerations during pregnancy'
         </a>
         below.)
        </p>
        <p>
         Patients receiving antifungal therapy should be monitored. The type of monitoring depends upon the agent being used. (See
         <a class="local">
          'Patient monitoring'
         </a>
         below.)
        </p>
        <p>
         <em>
          T. marneffei
         </em>
         infection typically occurs in patients with HIV who have a low CD4 count and are not on effective antiretroviral therapy (ART). Such patients should receive ART in addition to antifungal therapy. ART should be initiated within one week of starting antifungal therapy; however, it is important to check for potential drug interactions, especially with azole agents. (See
         <a class="local">
          'When to initiate antiretroviral therapy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV"
         </a>
         .)
        </p>
        <p>
         For patients with immunocompromising conditions other than HIV, we try to optimize their cellular immunity by treating the underlying condition (eg, diabetes control, optimizing immunosuppressive therapy for autoimmune disease or cancer, etc). Although presence of anti-interferon gamma autoantibodies is common in some areas, no specific treatment is available.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Induction and consolidation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients should receive induction therapy for 2 weeks followed by consolidation therapy for 10 weeks. The approach to treatment depends upon the severity of disease. (See
         <a class="local">
          'Moderate to severe disease'
         </a>
         below and
         <a class="local">
          'Mild disease'
         </a>
         below.)
        </p>
        <p>
         After induction and consolidation therapy, immunocompromised patients should transition to a maintenance therapy regimen. (See
         <a class="local">
          'Maintenance therapy (secondary prophylaxis)'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2814595043">
         <span class="h4">
          Moderate to severe disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonpregnant patients with moderate to severe disease should be treated initially with intravenous therapy and then transitioned to an oral azole-containing regimen. Considerations during pregnancy and patient monitoring during treatment are discussed below. (See
         <a class="local">
          'Considerations during pregnancy'
         </a>
         below and
         <a class="local">
          'Patient monitoring'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preferred regimen
         </strong>
         – For patients with moderate to severe disease (eg, multiple organ involvement), we recommend induction therapy with amphotericin B for two weeks. We suggest
         <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">
          liposomal amphotericin B
         </a>
         (3 to 5 mg/kg/day) rather than
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         . However, amphotericin B deoxycholate (0.7 to 1.0 mg/kg/day) is an alternative when lipid formulations are not available. Although there are no studies comparing liposomal versus conventional amphotericin in patients with talaromycosis, liposomal amphotericin is associated with less toxicity (eg, nephrotoxicity, infusion reactions, anemia) compared with the deoxycholate formulation; in addition, its use for treatment of talaromycosis has been described in case reports [
         <a href="#rid38">
          38,39
         </a>
         ]. A more detailed discussion of amphotericin B is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/476.html" rel="external">
          "Pharmacology of amphotericin B"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         After completing two weeks of amphotericin B, patients should be transitioned to consolidation therapy with oral
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         (200 mg twice daily) for 10 weeks. The oral solution of itraconazole is preferred to the capsule in order to achieve better absorption. When initiating itraconazole, we administer a loading dose of 200 mg three times daily for three days and then reduce to twice daily therapy to help achieve therapeutic levels, although not all experts use a loading dose [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/495.html" rel="external">
          "Pharmacology of azoles"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The use of a regimen that includes amphotericin B followed by
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         has been supported by several studies [
         <a href="#rid5">
          5,37,40-42
         </a>
         ]. As an example, in an open-label, noncomparative report of 74 patients with HIV (mean CD4 count 64 cells/microL) who received amphotericin B for two weeks followed by oral itraconazole for 10 weeks, 72 (97 percent) responded without serious adverse effects [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The importance of induction therapy with amphotericin B was highlighted in an open-label randomized trial that compared amphotericin B with
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         during the first two weeks of therapy [
         <a href="#rid42">
          42
         </a>
         ]. In this trial, 440 patients with AIDS (median CD4 count 10 cells/microL) and talaromycosis received 14 days of induction therapy with either
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         (0.7 to 1.0 mg/kg/day) or itraconazole (300 mg twice daily for three days then 200 mg twice daily for 11 days). All patients then received twice-daily itraconazole for 10 weeks followed by once-daily itraconazole until the CD4 count was &gt;100 cells/microL for at least six months. There was no significant difference in mortality at two weeks (absolute risk difference [ARD] 0.9 percent, 95% CI 3.9-5.9); however, by 24 weeks, the risk of death was significantly lower among those who had received amphotericin B (11 versus 21 percent, ARD 9.7 percent, 95% CI 2.8 to 16.6). This difference was felt to be due, in part, to faster fungal clearance with amphotericin B. Although patients who received amphotericin B were significantly more likely to have infusion-related reactions and laboratory abnormalities, the number of serious adverse events was similar between the groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alternative regimen
         </strong>
         –
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          Voriconazole
         </a>
         is an alternative treatment for patients with moderate to severe disease who cannot tolerate amphotericin B [
         <a href="#rid5">
          5,43-47
         </a>
         ]. Induction therapy with intravenous voriconazole (6 mg/kg every 12 hours on day 1 followed by 4 mg/kg every 12 hours) should be administered for two weeks. If intravenous voriconazole is not available, oral voriconazole can be used (600 mg every 12 hours on day 1 and then 400 mg every 12 hours for 2 weeks). Patients can then be transitioned to consolidation therapy with oral voriconazole (200 mg twice daily) or
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         (200 mg twice daily) for an additional 10 weeks. More detailed information on treatment with azole therapy is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/495.html" rel="external">
          "Pharmacology of azoles"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H51670164">
         <span class="h4">
          Mild disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For nonpregnant patients with mild disease (ie, only skin lesions and no fungemia), we suggest oral
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         for 12 weeks without amphotericin B. We administer a loading dose of 200 mg three times daily for three days and then reduce to twice-daily therapy. We prefer the oral solution of itraconazole rather than the capsule.
        </p>
        <p>
         If
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         cannot be used, patients with mild disease can be treated with oral
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         . Oral voriconazole should be administered as 400 mg twice per day on day 1 followed by 200 mg twice daily for 12 weeks [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         Considerations during pregnancy and monitoring of drug levels during treatment are discussed below. (See
         <a class="local">
          'Considerations during pregnancy'
         </a>
         below and
         <a class="local">
          'Patient monitoring'
         </a>
         below.)
        </p>
        <p>
         We prefer induction therapy with
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         rather than amphotericin B for patients with mild disease; this approach has been supported by several reports [
         <a href="#rid36">
          36,43,48
         </a>
         ] and reduces the need for admission and parenteral therapy. Although the randomized trial described above found that amphotericin B induction therapy is better than oral itraconazole regardless of disease severity [
         <a href="#rid42">
          42
         </a>
         ], there was no mortality benefit of amphotericin B at 2 or 24 weeks among those without evidence of fungemia.
        </p>
        <p class="headingAnchor" id="H511569381">
         <span class="h3">
          Maintenance therapy (secondary prophylaxis)
         </span>
        </p>
        <p class="headingAnchor" id="H2151246566">
         <span class="h4">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         For immunocompromised hosts, we recommend maintenance therapy after induction and consolidation therapy have been completed. (See
         <a class="local">
          'Regimen'
         </a>
         below and
         <a class="local">
          'Duration'
         </a>
         below.)
        </p>
        <p>
         In patients with HIV, relapses of
         <em>
          T. marneffei
         </em>
         infection were common before the introduction of potent ART. In one study, the relapse rate was 50 percent after treatment was discontinued [
         <a href="#rid48">
          48
         </a>
         ]. The efficacy of
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         maintenance therapy was illustrated in a randomized trial conducted from 1993 to 1996 that included 71 patients with AIDS (none of whom were taking ART) and disseminated, culture-proven
         <em>
          T. marneffei
         </em>
         infection [
         <a href="#rid49">
          49
         </a>
         ]. In this trial patients received oral itraconazole (200 mg daily) or placebo after successful completion of standard antifungal therapy. The study was terminated after the interim analysis, since all 20 relapses of
         <em>
          T. marneffei
         </em>
         infection occurred in the placebo group.
        </p>
        <p>
         On rare occasion, apparently immunocompetent hosts can present with talaromycosis. For such patients, we do not administer maintenance therapy after induction and consolidation therapy have been completed.
        </p>
        <p class="headingAnchor" id="H3275046880">
         <span class="h4">
          Regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         For nonpregnant patients, we administer
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         200 mg orally (PO) daily. For patients who cannot take itraconazole,
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         (200 mg PO twice daily) can be used; the dose of voriconazole should then be modified based upon serum levels. (See
         <a class="local">
          'Patient monitoring'
         </a>
         below.)
        </p>
        <p>
         Considerations for treatment during pregnancy are discussed below. (See
         <a class="local">
          'Considerations during pregnancy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3426352371">
         <span class="h4">
          Duration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with talaromycosis should receive long-term maintenance therapy until they have had restoration of cellular immunity.
        </p>
        <p>
         For patients with HIV receiving potent ART, we suggest maintenance therapy be continued until both the HIV viral load is suppressed and the CD4 count is ≥100 cells/microL for a minimum of six months. Secondary prophylaxis should be reintroduced if the CD4 count decreases to &lt;100 cells/microL.
        </p>
        <p class="bulletIndent1">
         This approach is supported through small case series and retrospective studies. As an example, in a retrospective cohort study of 33 patients with AIDS receiving ART who achieved a CD4 cell count of ≥100 cells/microL for at least six months, no relapses were observed after a median follow-up of 18 months (range 6 to 45 months) [
         <a href="#rid50">
          50
         </a>
         ]. In another study of 26 patients with talaromycosis, 18 patients discontinued maintenance therapy after their CD4 count had increased to a median of 95 cells/microL, and only one patient relapsed after a median follow-up of 35 months, despite this low level of immune reconstitution [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3643217856">
         <span class="h3">
          Considerations during pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to treatment of talaromycosis during pregnancy depends upon fetal maturity and can be complex given the risk of teratogenicity with azole agents and the risk of toxicity with amphotericin B.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         During the first trimester, patients should receive therapy with amphotericin B (even those with mild disease). Therapy with an azole antifungal is contraindicated during the first trimester because of the risk of teratogenicity. (See
         <a class="medical medical_review" href="/z/d/html/495.html" rel="external">
          "Pharmacology of azoles", section on 'Pregnancy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         After the first trimester, the decision to initiate an azole or continue amphotericin B must be determined on a case-by-case basis since the risk of teratogenicity after the first trimester is less clear.
        </p>
        <p>
        </p>
        <p>
         Such patients should be managed in conjunction with a maternal-fetal medicine specialist and an infectious diseases specialist to help balance the risks and benefits of the different treatment options. (See
         <a class="medical medical_review" href="/z/d/html/476.html" rel="external">
          "Pharmacology of amphotericin B"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/495.html" rel="external">
          "Pharmacology of azoles", section on 'Serum drug concentration monitoring'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Patient monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients being treated for talaromycosis, the type of monitoring depends upon the agent being used and the availability of testing. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients treated with amphotericin B should be monitored for infusion-related adverse reactions, nephrotoxicity, and electrolyte disturbances.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients receiving
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         , serum itraconazole levels should be obtained to ensure adequate absorption, especially if potential drug interactions exist [
         <a href="#rid5">
          5
         </a>
         ]. A random serum level should be about 2 mcg/mL performed by high-pressure liquid chromatography.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         is used, serum trough levels should be monitored and maintained between 1 and 5 mcg/mL to help ensure efficacy and avoid the toxicity seen with higher levels.
        </p>
        <p>
        </p>
        <p>
         More detailed discussions regarding monitoring (eg, when serum drug levels should be obtained) are found in specific topic reviews within UpToDate. (See
         <a class="medical medical_review" href="/z/d/html/476.html" rel="external">
          "Pharmacology of amphotericin B"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/495.html" rel="external">
          "Pharmacology of azoles", section on 'Serum drug concentration monitoring'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H511569222">
         <span class="h2">
          When to initiate antiretroviral therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antiretroviral therapy (ART) should be initiated in patients with HIV who are not receiving HIV therapy. (See
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         .)
        </p>
        <p>
         ART can be started approximately one week after initiating antifungal treatment [
         <a href="#rid5">
          5
         </a>
         ]. This approach is based upon expert opinion, since there are no data to guide this decision in patients with talaromycosis. A more detailed discussion of when to initiate ART is found in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/3777.html" rel="external">
          "When to initiate antiretroviral therapy in persons with HIV"
         </a>
         .)
        </p>
        <p>
         When choosing a regimen, it is necessary to check for potential drug interactions between
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         or
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         and antiretroviral medications, since certain ART agents can either increase or decrease antifungal levels. (See
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/495.html" rel="external">
          "Pharmacology of azoles", section on 'Drug interactions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H511568871">
         <span class="h2">
          Recurrent infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         If a patient has a recurrence of talaromycosis, a complete course of induction and consolidation therapy should be repeated followed by maintenance therapy. (See
         <a class="local">
          'Induction and consolidation therapy'
         </a>
         above and
         <a class="local">
          'Maintenance therapy (secondary prophylaxis)'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most effective way to prevent talaromycosis is by improving the immune system through the use of antiretroviral therapy (ART) in those living with HIV and/or management of other immunocompromised conditions. (See
         <a class="medical medical_review" href="/z/d/html/3777.html" rel="external">
          "When to initiate antiretroviral therapy in persons with HIV"
         </a>
         .)
        </p>
        <p>
         Until some degree of immune recovery is achieved (eg, CD4 count ≥100 cells/microL), the use of antifungal therapy (primary prophylaxis) is indicated for certain patients who are from endemic areas; others should avoid travel to these areas [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3033.html" rel="external">
          "Epidemiology and clinical manifestations of Talaromyces (Penicillium) marneffei infection", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H511568921">
         <span class="h2">
          Initiating primary prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest primary prophylaxis for nonpregnant patients with HIV and a CD4 count &lt;100 cells/microL who:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Are unable to initiate HIV treatment or have HIV treatment failure without access to effective ART options.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          AND
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Live in or travel to areas of high endemicity. These areas include rural areas in northern Thailand, Vietnam, and southern China [
         <a href="#rid5">
          5,52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3033.html" rel="external">
          "Epidemiology and clinical manifestations of Talaromyces (Penicillium) marneffei infection", section on 'Endemicity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         For patients residing in endemic areas, we administer
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         200 mg orally (PO) once daily. We prefer itraconazole solution because it is better absorbed. An alternative regimen is
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         400 mg PO once weekly. In one retrospective study, these two regimens demonstrated comparable efficacy for primary prophylaxis [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         For individuals who travel to an endemic area,
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         can be started three days before travel and continued for one week after leaving the endemic area. If
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         is used, it should be started three days before travel and continued once weekly while in the area, and the final dose should be administered after leaving the area.
        </p>
        <p>
         For pregnant patients, primary prophylaxis is generally not warranted, since all efforts should be focused on initiating ART and there are risks associated with azole therapy. (See
         <a class="medical medical_review" href="/z/d/html/3799.html" rel="external">
          "Prevention of vertical HIV transmission in resource-limited settings"
         </a>
         and
         <a class="local">
          'Considerations during pregnancy'
         </a>
         above.)
        </p>
        <p>
         The use of primary prophylaxis in high-risk populations is based upon the results of a randomized trial in 129 Thai patients with a mean CD4 count of 77 cells/microL [
         <a href="#rid54">
          54
         </a>
         ]. Patients received
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         (200 mg daily) or placebo; most were not receiving ART during the study. In the intent-to-treat analysis, the proportion of patients who developed a systemic fungal infection was significantly lower in the prophylaxis arm compared with the placebo arm (1.6 versus 16.7 percent). One patient in the itraconazole arm and four patients in the placebo arm developed
         <em>
          T. marneffei
         </em>
         infection; however, no survival advantage was observed in the itraconazole arm.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Discontinuation of primary prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary prophylaxis can be discontinued in patients receiving ART when the CD4 count is ≥100 cells/microL for at least six months. This approach is supported by guideline panels and is based upon data that evaluated discontinuing maintenance therapy [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="local">
          'Maintenance therapy (secondary prophylaxis)'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H73098293">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111612.html" rel="external">
          "Society guideline links: Opportunistic infections in adults with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nomenclature
         </strong>
         –
         <em>
          Talaromyces
         </em>
         <em>
          marneffei
         </em>
         (formerly
         <em>
          Penicillium marneffei
         </em>
         ) is an important cause of morbidity and mortality in patients with AIDS or other immunocompromising conditions who live in or are from endemic areas (eg, Southeast Asia).
         <em>
          Penicillium
         </em>
         <em>
          marneffei
         </em>
         was renamed
         <em>
          Talaromyces marneffei
         </em>
         in 2015, and the disease, which had been referred to as penicilliosis, is now called talaromycosis. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Approach to diagnosis
         </strong>
         – The diagnosis of talaromycosis infection should be considered in immunocompromised patients, particularly those with AIDS, who are from Southeast Asia, northern Australia, South Asia (including India), and China. Although talaromycosis typically occurs in patients who are severely immunocompromised, cases have also been reported in those with other underlying conditions (eg, autoimmune disorders, cancer, diabetes). (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Definitive diagnosis
         </strong>
         – A definitive diagnosis is made by culturing the fungus, most commonly from blood, skin biopsy, bone marrow, or lymph nodes.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Presumptive diagnosis
         </strong>
         – A presumptive diagnosis can be made on histopathology in the appropriate clinical and epidemiologic setting. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Evaluation for immunocompromising conditions
         </strong>
         – For patients with talaromycosis and no known immunocompromise, we evaluate for immunocompromise by performing a history and physical, age-appropriate cancer screening, and testing for HIV, diabetes, autoimmune diseases, and presence of anti-interferon gamma autoantibody.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to treatment
         </strong>
         – Antifungal therapy should be initiated as soon as possible in patients with talaromycosis. A high mortality has been reported if the infection goes untreated, or if there is a delay in diagnosis, especially in patients with moderate or severe disease. Patients with talaromycosis should receive an initial course of induction therapy followed by consolidation therapy. Maintenance therapy should be continued in immunocompromised hosts. (See
         <a class="local">
          'Indications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Induction therapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with moderate to severe disease (eg, multiple organ involvement), we recommend two weeks of induction therapy with amphotericin B rather than an alternative antifungal agent (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). We prefer
         <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">
          liposomal amphotericin B
         </a>
         (3 to 5 mg/kg/day) rather than
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         to reduce the risk of toxicity (eg, nephrotoxicity, infusion reactions, anemia). (See
         <a class="local">
          'Moderate to severe disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with mild infection (ie, only skin lesions and no fungemia), we suggest induction therapy with
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         rather than an alternative antifungal agent (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Mild disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Consolidation therapy
         </strong>
         – For all patients, we suggest consolidation therapy with
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         for 10 weeks (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Observation studies suggest that a total of 12 weeks of therapy (induction plus consolidation) is associated with clinical improvement. (See
         <a class="local">
          'Induction and consolidation therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Maintenance therapy
         </strong>
         – For immunocompromised patients, we recommend maintenance antifungal therapy after induction and consolidation therapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). In such patients, maintenance therapy significantly reduces the risk of relapse. The standard regimen is
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         200 mg daily. Maintenance therapy should be continued until restoration of cellular immunity has occurred. For patients with HIV receiving antiretroviral therapy (ART), we continue maintenance therapy until the HIV viral load is suppressed and the CD4 count is ≥100 cells/microL for at least six months. (See
         <a class="local">
          'Duration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pregnant individuals
         </strong>
         – The approach to treatment of talaromycosis during pregnancy depends upon fetal maturity and can be complex given the potential risk of teratogenicity with azole agents and the risk of toxicity with amphotericin B. Such patients should be managed in conjunction with a maternal-fetal medicine specialist and an infectious diseases specialist to help balance the risks and benefits of the different treatment options. (See
         <a class="local">
          'Considerations during pregnancy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initiating ART in patients with HIV
         </strong>
         – In patients with HIV who are not receiving HIV therapy, ART should be initiated in addition to antifungal therapy. We suggest starting ART approximately one week after initiating antifungal treatment (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). When choosing an ART regimen, it is necessary to check for potential drug interactions with antifungal agents. (See
         <a class="local">
          'When to initiate antiretroviral therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary prophylaxis
         </strong>
         – For nonpregnant patients with HIV and a CD4 count &lt;100 cells/microL who live in or travel to areas of high endemicity and are unable to initiate ART or have virologic failure without access to effective ART options, we suggest primary prophylaxis with
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). For such patients, available data suggest primary prophylaxis decreases the risk of developing infection with
         <em>
          T. marneffei
         </em>
         . (See
         <a class="local">
          'Initiating primary prophylaxis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1883208384">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Thira Sirisanthana, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Supparatpinyo K, Khamwan C, Baosoung V, et al. Disseminated Penicillium marneffei infection in southeast Asia. Lancet 1994; 344:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawila R, Chaiwarith R, Supparatpinyo K. Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study. BMC Infect Dis 2013; 13:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Browne SK, Burbelo PD, Chetchotisakd P, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med 2012; 367:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shi N, Kong J, Wang K, Cao C. Coinfection With Talaromyces marneffei and Other Pathogens Associated With Acquired Immunodeficiency. JAMA Dermatol 2019; 155:1195.
          </a>
         </li>
         <li class="breakAll">
          Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on August 07, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Supparatpinyo K, Sirisanthana T. Disseminated Penicillium marneffei infection diagnosed on examination of a peripheral blood smear of a patient with human immunodeficiency virus infection. Clin Infect Dis 1994; 18:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hung YT, Yang SP. Pancytopenia in a Southeast Asian Woman with HIV Infection. Clin Infect Dis 2009; 49:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jayanetra P, Nitiyanant P, Ajello L, et al. Penicilliosis marneffei in Thailand: report of five human cases. Am J Trop Med Hyg 1984; 33:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           So SY, Chau PY, Jones BM, et al. A case of invasive penicilliosis in Hong Kong with immunologic evaluation. Am Rev Respir Dis 1985; 131:662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Louthrenoo W, Thamprasert K, Sirisanthana T. Osteoarticular penicilliosis marneffei. A report of eight cases and review of the literature. Br J Rheumatol 1994; 33:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanittanakom N, Vanittanakom P, Hay RJ. Rapid identification of Penicillium marneffei by PCR-based detection of specific sequences on the rRNA gene. J Clin Microbiol 2002; 40:1739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sekhon AS, Li JS, Garg AK. Penicillosis marneffei: serological and exoantigen studies. Mycopathologia 1982; 77:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chariyalertsak S, Sirisanthana T, Supparatpinyo K, et al. Case-control study of risk factors for Penicillium marneffei infection in human immunodeficiency virus-infected patients in northern Thailand. Clin Infect Dis 1997; 24:1080.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heath TC, Patel A, Fisher D, et al. Disseminated Penicillium marneffei: presenting illness of advanced HIV infection; a clinicopathological review, illustrated by a case report. Pathology 1995; 27:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yousukh A, Jutavijittum P, Pisetpongsa P, et al. Clinicopathologic study of hepatic Penicillium marneffei in Northern Thailand. Arch Pathol Lab Med 2004; 128:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaiwun B, Khunamornpong S, Sirivanichai C, et al. Lymphadenopathy due to Penicillium marneffei infection: diagnosis by fine needle aspiration cytology. Mod Pathol 2002; 15:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanittanakom N, Sirisanthana T. Penicillium marneffei infection in patients infected with human immunodeficiency virus. Curr Top Med Mycol 1997; 8:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cao L, Chan KM, Chen D, et al. Detection of cell wall mannoprotein Mp1p in culture supernatants of Penicillium marneffei and in sera of penicilliosis patients. J Clin Microbiol 1999; 37:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanittanakom N, Mekaprateep M, Sittisombut N, et al. Western immunoblot analysis of protein antigens of Penicillium marneffei. J Med Vet Mycol 1997; 35:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wheat LJ. Antigen detection, serology, and molecular diagnosis of invasive mycoses in the immunocompromised host. Transpl Infect Dis 2006; 8:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaiyaroj SC, Chawengkirttikul R, Sirisinha S, et al. Antigen detection assay for identification of Penicillium marneffei infection. J Clin Microbiol 2003; 41:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanittanakom N, Merz WG, Sittisombut N, et al. Specific identification of Penicillium marneffei by a polymerase chain reaction/hybridization technique. Med Mycol 1998; 36:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaufman L, Standard PG, Jalbert M, et al. Diagnostic antigenemia tests for penicilliosis marneffei. J Clin Microbiol 1996; 34:2503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LoBuglio KF, Taylor JW. Phylogeny and PCR identification of the human pathogenic fungus Penicillium marneffei. J Clin Microbiol 1995; 33:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prariyachatigul C, Chaiprasert A, Geenkajorn K, et al. Development and evaluation of a one-tube seminested PCR assay for the detection and identification of Penicillium marneffei. Mycoses 2003; 46:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Desakorn V, Simpson AJ, Wuthiekanun V, et al. Development and evaluation of rapid urinary antigen detection tests for diagnosis of penicilliosis marneffei. J Clin Microbiol 2002; 40:3179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsunemi Y, Takahashi T, Tamaki T. Penicillium marneffei infection diagnosed by polymerase chain reaction from the skin specimen. J Am Acad Dermatol 2003; 49:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang YT, Hung CC, Liao CH, et al. Detection of circulating galactomannan in serum samples for diagnosis of Penicillium marneffei infection and cryptococcosis among patients infected with human immunodeficiency virus. J Clin Microbiol 2007; 45:2858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang YT, Hung CC, Hsueh PR. Aspergillus galactomannan antigenemia in penicilliosis marneffei. AIDS 2007; 21:1990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanittanakom N, Cooper CR Jr, Fisher MC, Sirisanthana T. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev 2006; 19:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thu NTM, Chan JFW, Ly VT, et al. Superiority of a Novel Mp1p Antigen Detection Enzyme Immunoassay Compared to Standard BACTEC Blood Culture in the Diagnosis of Talaromycosis. Clin Infect Dis 2021; 73:e330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mootsikapun P, Srikulbutr S. Histoplasmosis and penicilliosis: comparison of clinical features, laboratory findings and outcome. Int J Infect Dis 2006; 10:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wheat J, Wheat H, Connolly P, et al. Cross-reactivity in Histoplasma capsulatum variety capsulatum antigen assays of urine samples from patients with endemic mycoses. Clin Infect Dis 1997; 24:1169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tobar Vega P, Erramilli S, Lee E. Talaromyces marneffei laboratory cross reactivity with Histoplasma and Blastomyces urinary antigen. Int J Infect Dis 2019; 86:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Supparatpinyo K, Nelson KE, Merz WG, et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother 1993; 37:2407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ranjana KH, Priyokumar K, Singh TJ, et al. Disseminated Penicillium marneffei infection among HIV-infected patients in Manipur state, India. J Infect 2002; 45:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sirisanthana T, Supparatpinyo K, Perriens J, Nelson KE. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 26:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang JL, Hung CC, Chang SC, et al. Disseminated Penicillium marneffei infection in a renal-transplant recipient successfully treated with liposomal amphotericin B. Transplantation 2003; 76:1136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vergidis P, Rao A, Moore CB, et al. Talaromycosis in a renal transplant recipient returning from South China. Transpl Infect Dis 2021; 23:e13447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Abdely HM. Management of rare fungal infections. Curr Opin Infect Dis 2004; 17:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le T, Huu Chi N, Kim Cuc NT, et al. AIDS-associated Penicillium marneffei infection of the central nervous system. Clin Infect Dis 2010; 51:1458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le T, Kinh NV, Cuc NTK, et al. A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis. N Engl J Med 2017; 376:2329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006; 43:1060.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Supparatpinyo K, Schlamm HT. Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients. Am J Trop Med Hyg 2007; 77:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ouyang Y, Cai S, Liang H, Cao C. Administration of Voriconazole in Disseminated Talaromyces (Penicillium) Marneffei Infection: A Retrospective Study. Mycopathologia 2017; 182:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ge Y, Xu Z, Hu Y, Huang M. Successful voriconazole treatment of Talaromyces marneffei infection in an HIV-negative patient with osteolytic lesions. J Infect Chemother 2019; 25:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Supparatpinyo K, Chiewchanvit S, Hirunsri P, et al. An efficacy study of itraconazole in the treatment of Penicillium marneffei infection. J Med Assoc Thai 1992; 75:688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Supparatpinyo K, Perriens J, Nelson KE, Sirisanthana T. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med 1998; 339:1739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaiwarith R, Charoenyos N, Sirisanthana T, Supparatpinyo K. Discontinuation of secondary prophylaxis against penicilliosis marneffei in AIDS patients after HAART. AIDS 2007; 21:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun HY, Chen MY, Hsiao CF, et al. Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated with highly active anti-retroviral therapy. Clin Microbiol Infect 2006; 12:381.
          </a>
         </li>
         <li class="breakAll">
          Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. http://abm.digitaljournals.org/index.php/abm/article/viewFile/543/398 (Accessed on May 21, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaiwarith R, Fakthongyoo A, Praparattanapan J, et al. Itraconazole vs fluconazole as a primary prophylaxis for fungal infections in HIV-infected patients in Thailand. Curr HIV Res 2011; 9:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002; 34:277.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3035 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7912350" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Disseminated Penicillium marneffei infection in southeast Asia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24094273" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22913682" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Adult-onset immunodeficiency in Thailand and Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31339513" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Coinfection With Talaromyces marneffei and Other Pathogens Associated With Acquired Immunodeficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31339513" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Coinfection With Talaromyces marneffei and Other Pathogens Associated With Acquired Immunodeficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8161635" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Disseminated Penicillium marneffei infection diagnosed on examination of a peripheral blood smear of a patient with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19500026" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Pancytopenia in a Southeast Asian Woman with HIV Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6476209" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Penicilliosis marneffei in Thailand: report of five human cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3873195" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A case of invasive penicilliosis in Hong Kong with immunologic evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8000744" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Osteoarticular penicilliosis marneffei. A report of eight cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11980953" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Rapid identification of Penicillium marneffei by PCR-based detection of specific sequences on the rRNA gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6175904" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Penicillosis marneffei: serological and exoantigen studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9195061" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Case-control study of risk factors for Penicillium marneffei infection in human immunodeficiency virus-infected patients in northern Thailand.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7603743" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Disseminated Penicillium marneffei: presenting illness of advanced HIV infection; a clinicopathological review, illustrated by a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14736284" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Clinicopathologic study of hepatic Penicillium marneffei in Northern Thailand.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12218211" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Lymphadenopathy due to Penicillium marneffei infection: diagnosis by fine needle aspiration cytology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9504065" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Penicillium marneffei infection in patients infected with human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10074513" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Detection of cell wall mannoprotein Mp1p in culture supernatants of Penicillium marneffei and in sera of penicilliosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9147272" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Western immunoblot analysis of protein antigens of Penicillium marneffei.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16913971" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Antigen detection, serology, and molecular diagnosis of invasive mycoses in the immunocompromised host.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12517886" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Antigen detection assay for identification of Penicillium marneffei infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9776830" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Specific identification of Penicillium marneffei by a polymerase chain reaction/hybridization technique.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8880509" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Diagnostic antigenemia tests for penicilliosis marneffei.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7699073" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Phylogeny and PCR identification of the human pathogenic fungus Penicillium marneffei.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14641616" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Development and evaluation of a one-tube seminested PCR assay for the detection and identification of Penicillium marneffei.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12202550" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Development and evaluation of rapid urinary antigen detection tests for diagnosis of penicilliosis marneffei.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12894097" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Penicillium marneffei infection diagnosed by polymerase chain reaction from the skin specimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17596363" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Detection of circulating galactomannan in serum samples for diagnosis of Penicillium marneffei infection and cryptococcosis among patients infected with human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17721116" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Aspergillus galactomannan antigenemia in penicilliosis marneffei.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16418525" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32564074" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Superiority of a Novel Mp1p Antigen Detection Enzyme Immunoassay Compared to Standard BACTEC Blood Culture in the Diagnosis of Talaromycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16242368" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Histoplasmosis and penicilliosis: comparison of clinical features, laboratory findings and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9195077" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Cross-reactivity in Histoplasma capsulatum variety capsulatum antigen assays of urine samples from patients with endemic mycoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31229614" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Talaromyces marneffei laboratory cross reactivity with Histoplasma and Blastomyces urinary antigen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8285625" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12423616" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Disseminated Penicillium marneffei infection among HIV-infected patients in Manipur state, India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9597237" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14557769" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Disseminated Penicillium marneffei infection in a renal-transplant recipient successfully treated with liposomal amphotericin B.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32794335" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Talaromycosis in a renal transplant recipient returning from South China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15640706" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Management of rare fungal infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21054180" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : AIDS-associated Penicillium marneffei infection of the central nervous system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28614691" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16983621" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12715306" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Voriconazole treatment for less-common, emerging, or refractory fungal infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17690411" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28108867" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Administration of Voriconazole in Disseminated Talaromyces (Penicillium) Marneffei Infection: A Retrospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30195473" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Successful voriconazole treatment of Talaromyces marneffei infection in an HIV-negative patient with osteolytic lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1339213" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : An efficacy study of itraconazole in the treatment of Penicillium marneffei infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9845708" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17255744" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Discontinuation of secondary prophylaxis against penicilliosis marneffei in AIDS patients after HAART.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16524416" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated with highly active anti-retroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16524416" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated with highly active anti-retroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21916838" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Itraconazole vs fluconazole as a primary prophylaxis for fungal infections in HIV-infected patients in Thailand.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11740718" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
